Table 2.
Baseline description
| Variable | Value | All (n = 1,309), n (%) or median (IQR) |
|---|---|---|
| Sex | Female | 624 (47.7) |
| Male | 681 (52.2) | |
| Age at diagnosis | 54.1 (41.8–64.2) | |
| Time since diagnosis | 2.3 (0.7–5.9) | |
| Sarcoma type | STS | 910 (69.7) |
| BS | 236 (18.1) | |
| GIST | 159 (12.2) | |
| Site | Trunk | 629 (48.2) |
| Limbs | 610 (46.7) | |
| Somewhere else | 66 (5.1) | |
| Grading | Low grade | 158 (12.1) |
| High grade | 705 (53.9) | |
| Not accessible/unknown/not graded | 446 (34.1) | |
| Malignancy of the tumor | Locally aggressive and rarely metastatic | 108 (8.3) |
| Malignant | 1,197 (91.7) | |
| Metastasis at diagnosis | No | 928 (71.4) |
| Yes | 133 (10.2) | |
| Unknown | 238 (18.3) | |
| Tumor recurrence | No recurrence | 947 (72.6) |
| Recurrence | 324 (24.8) | |
| Suspicion | 13 (1.0) | |
| Unknown | 21 (1.6) | |
| Treatment intention | Curative | 964 (73.9) |
| Palliative | 311 (23.8) | |
| Unknown | 29 (2.2) | |
| Disease status | Complete remission | 579 (44.4) |
| Partial remission/stable disease | 379 (29.0) | |
| Progress | 194 (14.9) | |
| Unknown | 153 (11.7) | |
| Treatment status | In treatment | 418 (32.1) |
| Not in treatment | 878 (67.3) | |
| Unknown | 8 (0.6) | |
| Surgery | No | 158 (12.1) |
| Yes | 1,137 (87.2) | |
| Unknown | 10 (0.8) | |
| Chemotherapy | No | 686 (52.6) |
| Yes | 602 (46.2) | |
| Unknown | 16 (1.2) | |
| Radiotherapy | No | 775 (59.4) |
| Yes | 498 (38.2) | |
| Unknown | 32 (2.5) | |
| Tyrosine kinase inhibitor | No | 1,055 (80.8) |
| Yes | 202 (15.5) | |
| Unknown | 48 (3.7) |